Targeting the tumour stroma to improve cancer therapy

被引:831
作者
Valkenburg, Kenneth C. [1 ]
de Groot, Amber E. [1 ,2 ]
Pienta, Kenneth J. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
关键词
FIBROBLAST ACTIVATION PROTEIN; MESENCHYMAL STEM-CELLS; PANCREATIC STELLATE CELLS; GROWTH-FACTOR-BETA; CARCINOMA-ASSOCIATED FIBROBLASTS; RESISTANCE CAM-DR; GENE-EXPRESSION SIGNATURE; METASTATIC COLON-CANCER; ADULT HUMAN FIBROBLASTS; PROSTATE-CANCER;
D O I
10.1038/s41571-018-0007-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancers are not composed merely of cancer cells alone; instead, they are complex 'ecosystems' comprising many different cell types and noncellular factors. The tumour stroma is a critical component of the tumour microenvironment, where it has crucial roles in tumour initiation, progression, and metastasis. Most anticancer therapies target cancer cells specifically, but the tumour stroma can promote the resistance of cancer cells to such therapies, eventually resulting in fatal disease. Therefore, novel treatment strategies should combine anticancer and antistromal agents. Herein, we provide an overview of the advances in understanding the complex cancer cell-tumour stroma interactions and discuss how this knowledge can result in more effective therapeutic strategies, which might ultimately improve patient outcomes.
引用
收藏
页码:366 / 381
页数:16
相关论文
共 331 条
[1]   Mesenchymal reprogramming of adult human epithelial differentiation [J].
Aboseif, S ;
El-Sakka, A ;
Young, P ;
Cunha, G .
DIFFERENTIATION, 1999, 65 (02) :113-118
[2]  
Alberts B., 2017, MOL BIOL CELL
[3]   Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts [J].
Albrengues, Jean ;
Bertero, Thomas ;
Grasset, Eloise ;
Bonan, Stephanie ;
Maiel, Majdi ;
Bourget, Isabelle ;
Philippe, Claude ;
Serrano, Cecilia Herraiz ;
Benamar, Samia ;
Croce, Olivier ;
Sanz-Moreno, Victoria ;
Meneguzzi, Guerrino ;
Feral, Chloe C. ;
Cristofari, Gael ;
Gaggioli, Cedric .
NATURE COMMUNICATIONS, 2015, 6
[4]   LIF Mediates Proinvasive Activation of Stromal Fibroblasts in Cancer [J].
Albrengues, Jean ;
Bourget, Isabelle ;
Pons, Catherine ;
Butet, Vincent ;
Hofman, Paul ;
Tartare-Deckert, Sophie ;
Feral, Chloe C. ;
Meneguzzi, Guerrino ;
Gaggioli, Cedric .
CELL REPORTS, 2014, 7 (05) :1664-1678
[5]   Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions [J].
Alexander, Jennifer ;
Cukierman, Edna .
CURRENT OPINION IN CELL BIOLOGY, 2016, 42 :80-93
[6]   Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance [J].
Alonso, Salvador ;
Hernandez, Daniela ;
Chang, Yu-Ting ;
Gocke, Christian D. ;
McCray, Megan ;
Varadhan, Ravi ;
Matsui, William H. ;
Jones, Richard J. ;
Ghiaur, Gabriel .
JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (12) :4460-4468
[7]   Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes [J].
Alonso, Salvador ;
Su, Meng ;
Jones, Jace W. ;
Ganguly, Sudipto ;
Kane, Maureen A. ;
Jones, Richard J. ;
Ghiaur, Gabriel .
ONCOTARGET, 2015, 6 (17) :14905-14912
[8]   Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential [J].
Alt, Eckhard ;
Yan, Yasheng ;
Gehmert, Sebastian ;
Song, Yao-Hua ;
Altman, Andrew ;
Gehmert, Sanga ;
Vykoukal, Daynene ;
Bai, Xiaowen .
BIOLOGY OF THE CELL, 2011, 103 (04) :197-208
[9]   Stromal disrupting effects of nab-paclitaxel in pancreatic cancer [J].
Alvarez, R. ;
Musteanu, M. ;
Garcia-Garcia, E. ;
Lopez-Casas, P. P. ;
Megias, D. ;
Guerra, C. ;
Munoz, M. ;
Quijano, Y. ;
Cubillo, A. ;
Rodriguez-Pascual, J. ;
Plaza, C. ;
de Vicente, E. ;
Prados, S. ;
Tabernero, S. ;
Barbacid, M. ;
Lopez-Rios, F. ;
Hidalgo, M. .
BRITISH JOURNAL OF CANCER, 2013, 109 (04) :926-933
[10]   Ecological paradigms to understand the dynamics of metastasis [J].
Amend, Sarah R. ;
Roy, Sounak ;
Brown, Joel S. ;
Pienta, Kenneth J. .
CANCER LETTERS, 2016, 380 (01) :237-242